Dose-response effects of marine XXXX on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and @entity6511 in individuals with moderate @entity2298 .

@entity2298 @entity32 @entity8393 @entity7784 @entity12436 @entity4600 @entity2204 @entity1674 @entity6511 @entity755 @entity4601 @entity16990 @entity1675 @entity9539 @entity3294 @entity731 @entity165
BACKGROUND: Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of @entity32 , such as @entity6511 ( @entity6511 ), influence the atherogenicity of circulating lipids and lipoproteins. Little evidence exists regarding the dose-response effects of the marine @entity9539 @entity7784 ( @entity8393 ) and @entity4600 ( @entity4601 ) on apos, apo-defined Lps, and @entity6511 . OBJECTIVE: The purpose of this study was to compare the effects of 0, 0.85, and 3.4  g/d of @entity8393  +  @entity4601 on @entity6511 mass and activity in individuals with moderate @entity2298 . We also measured effects on concentrations of apoAI, @entity3294 , @entity755 , apoC, @entity16990 , and @entity2204 -defined Lp subclasses. METHODS: The study was a randomized, doubleblind, crossover design with 8-week treatment periods and 6-week washout periods. During the 3 treatment periods, subjects (n  =  25) received 0  g/d @entity8393  +  @entity4601 , 0.85  g/d @entity8393  +  @entity4601 (low dose), and 3.4  g/d @entity8393  +  @entity4601 (high dose) in random order. RESULTS: @entity755 and @entity12436 were significantly decreased by the high dose relative to placebo and low dose (P  <  .01), as was very low-density lipoprotein @entity165 (P  <  .005). The low dose had no effect on Lp outcomes compared with placebo. The high- and low-dose effects differed significantly for heparin-precipitated @entity12436 , LpB, LpA-I, and @entity755 / @entity1675 ratio (P  <  .05). There was a trend for a decreased @entity6511 mass with the high dose (P  =  .1). CONCLUSION: The effects of 3.4  g/d @entity8393  +  @entity4601 on @entity755 and @entity12436 may reduce @entity731 in individuals with elevated @entity1674 .
